BioPharm International releases new warnings about protecting against microbiological contamination throughout the manufacturing process.
In an article posted on the Process Development Forum, BioPharm International says manufacturers need to maintain bioburden control throughout the entire manufacturing plant to minimize the risk of contaminants entering medicinal products.
Adhering to cGMP requirements is stressed to ensure quality in both the product and the process.
MRA experts, with their extensive experience, can help clients meet the rigorous cGMP standards and bioburden control requirements to protect against microbiological contamination. Contact an MRA representative to learn more.